Bifogade filer
Alzecure AR 2025 ENG
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that its Annual Report for 2025 has been published.
”2025 was an active and positive year for AlzeCure Pharma. One of our main focus areas was to prepare the phase II study in Alzheimer’s patients with NeuroRestore ACD856, for which we were awarded a grant of 2.5 million euros from the European Innovation Council (EIC) at the beginning of the year. During the year, we also initiated a new Phase Ib clinical trial with ACD856 based on the compound’s favorable safety profile, which enables even higher dosages and may be relevant for other indication areas, including depression. We also worked on the preparations for a potential registration study for the pain project Painless ACD440, after we were granted orphan drug designation by both the U.S. Food and Drug Administration and the European Medicines Agency for the rare disease erythromelalgia. Furthermore, the company’s finances were strengthened through an oversubscribed rights issue of SEK 58.5 million – a vote of confidence in the current market. We are very proud of what we achieved in 2025, which provides a strong platform for 2026.”
Martin Jönsson
CEO of AlzeCure Pharma
The Annual Report is attached as a PDF and is available on the company’s website, https://www.alzecurepharma.se/en/section/investors/financial-reports/